Shares

34 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$1.96 - $2.9 $71,099 - $105,197
36,275 New
36,275 $93,000
Q3 2023

May 09, 2024

BUY
$1.19 - $2.26 $55,564 - $105,526
46,693 New
46,693 $80,000
Q2 2023

Apr 29, 2024

BUY
$1.66 - $3.03 $77,510 - $141,479
46,693 New
46,693 $91,000
Q2 2023

Aug 10, 2023

BUY
$1.66 - $3.03 $77,510 - $141,479
46,693 New
46,693 $91,000
Q1 2022

May 12, 2022

SELL
$4.03 - $12.19 $63,669 - $192,589
-15,799 Closed
0 $0
Q4 2021

May 17, 2024

BUY
$8.76 - $13.71 $47,391 - $74,171
5,410 Added 52.07%
15,799 $203,000
Q4 2021

Jun 21, 2023

BUY
$8.76 - $13.71 $138,399 - $216,604
15,799 New
15,799 $203,000
Q4 2021

Mar 22, 2023

BUY
$8.76 - $13.71 $47,391 - $74,171
5,410 Added 52.07%
15,799 $203,000
Q4 2021

Feb 15, 2022

BUY
$8.76 - $13.71 $47,391 - $74,171
5,410 Added 52.07%
15,799 $203,000
Q3 2021

May 17, 2024

SELL
$6.41 - $13.54 $38,876 - $82,120
-6,065 Reduced 36.86%
10,389 $112,000
Q3 2021

Jun 21, 2023

BUY
$6.41 - $13.54 $66,593 - $140,667
10,389 New
10,389 $112,000
Q3 2021

Mar 22, 2023

SELL
$6.41 - $13.54 $38,876 - $82,120
-6,065 Reduced 36.86%
10,389 $112,000
Q3 2021

Nov 15, 2021

SELL
$6.41 - $13.54 $38,876 - $82,120
-6,065 Reduced 36.86%
10,389 $112,000
Q2 2021

May 17, 2024

BUY
$8.13 - $10.2 $99,169 - $124,419
12,198 Added 286.61%
16,454 $150,000
Q2 2021

Jun 21, 2023

BUY
$8.13 - $10.2 $133,771 - $167,830
16,454 New
16,454 $150,000
Q2 2021

Mar 22, 2023

BUY
$8.13 - $10.2 $99,169 - $124,419
12,198 Added 286.61%
16,454 $150,000
Q2 2021

Aug 16, 2021

BUY
$8.13 - $10.2 $99,169 - $124,419
12,198 Added 286.61%
16,454 $150,000
Q1 2021

May 17, 2024

SELL
$4.07 - $27.11 $130,317 - $868,035
-32,019 Reduced 88.27%
4,256 $40,000
Q1 2021

Jun 26, 2023

BUY
$4.07 - $27.11 $17,321 - $115,380
4,256 New
4,256 $40.1 Million
Q1 2021

Mar 22, 2023

SELL
$4.07 - $27.11 $45,982 - $306,288
-11,298 Reduced 72.64%
4,256 $40,000
Q1 2021

May 14, 2021

BUY
$4.07 - $27.11 $17,321 - $115,380
4,256 New
4,256 $40,000
Q3 2020

Nov 13, 2020

SELL
$2.63 - $8.09 $40,907 - $125,831
-15,554 Closed
0 $0
Q2 2020

May 24, 2024

SELL
$5.69 - $8.17 $117,902 - $169,290
-20,721 Reduced 57.12%
15,554 $103 Million
Q2 2020

Jun 26, 2023

BUY
$5.69 - $8.17 $88,502 - $127,076
15,554 New
15,554 $103,000
Q2 2020

Mar 22, 2023

BUY
$5.69 - $8.17 $14,862 - $21,340
2,612 Added 20.18%
15,554 $103,000
Q2 2020

Aug 14, 2020

BUY
$5.69 - $8.17 $14,862 - $21,340
2,612 Added 20.18%
15,554 $103,000
Q1 2020

Jul 12, 2023

BUY
$5.47 - $11.3 $70,792 - $146,244
12,942 New
12,942 $75,000
Q1 2020

Mar 22, 2023

SELL
$5.47 - $11.3 $2,773 - $5,729
-507 Reduced 3.77%
12,942 $75,000
Q1 2020

May 15, 2020

BUY
$5.47 - $11.3 $70,792 - $146,244
12,942 New
12,942 $75,000
Q4 2019

Feb 14, 2020

SELL
$7.07 - $11.61 $95,084 - $156,142
-13,449 Closed
0 $0
Q3 2019

Jul 12, 2023

BUY
$8.45 - $12.28 $113,644 - $165,153
13,449 New
13,449 $116,000
Q3 2019

Mar 22, 2023

BUY
$8.45 - $12.28 $113,644 - $165,153
13,449 New
13,449 $116,000
Q3 2019

Nov 14, 2019

BUY
$8.45 - $12.28 $113,644 - $165,153
13,449 New
13,449 $116,000
Q2 2019

Jul 12, 2023

BUY
$9.2 - $15.7 $123,730 - $211,149
13,449 New
13,449 $150 Million

Others Institutions Holding GRTS

About Gritstone bio, Inc.


  • Ticker GRTS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,006,896
  • Market Cap $2.19M
  • Description
  • Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...
More about GRTS
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.